Diagnostic significance and considerations of growth hormone stimulation testing and insulin-like growth factor 1 in growth hormone deficiency / 中国当代儿科杂志

The growth hormone (GH)/insulin-like growth factor 1 (IGF-1) axis is an essential component of the hypothalamic-pituitary growth hormone axis and plays a crucial role in childhood growth and development. Disruptions and abnormalities in the GH/IGF-1 signaling pathway and its pathways typically manifest as short stature in children. Children with short stature often undergo GH stimulation testing and IGF-1 level measurements to differentiate growth hormone deficiency (GHD) from other causes of growth delay. This article aims to analyze and elucidate the values of GH stimulation testing and IGF-1 measurement, providing reference for the diagnosis of GHD in children.

Metabolomics as a potential tool for the diagnosis of growth hormone deficiency (GHD): a review

ABSTRACT Metabolomics uses several analytical tools to identify the chemical diversity of metabolites present in organisms. These metabolites are low molecular weight molecules (<1500 Da) classified as a final or intermediary product of metabolic processes. The application of this omics technology has become prominent in inferring physiological conditions through reporting on the phenotypic state; therefore, the introduction of metabolomics into clinical studies has been growing in recent years due to its efficiency in discriminating pathophysiological states. Regarding endocrine diseases, there is a great interest in verifying comprehensive and individualized physiological scenarios, in particular for growth hormone deficiency (GHD). The current GHD diagnostic tests are laborious and invasive and there is no exam with ideal reproducibility and sensitivity for diagnosis neither standard GH cut-off point. Therefore, this review was focussed on articles that applied metabolomics in the search for new biomarkers for GHD. The present work shows that the applications of metabolomics in GHD are still limited, since the little complementarily of analytical techniques, a low number of samples, GHD combined to other deficiencies, and idiopathic diagnosis shows a lack of progress. The results of the research are relevant and similar; however, their results do not provide an application for clinical practice due to the lack of multidisciplinary actions that would be needed to mediate the translation of the knowledge produced in the laboratory, if transferred to the medical setting.

Hormona de crecimiento en sangre de papel filtro para el diagnóstico de deficiencia de hormona de crecimiento / Growth hormone of dried blood spot for the diagnosis of growth hormone deficiency

INTRODUCCIÓN: El diagnóstico de deficiencia de hormona de crecimiento (DHC) es difícil de establecer, y se puede asociar a serias complicaciones, especialmente en el período neonatal. La prueba de estímulo de secreción de hormona de crecimiento (HC) se considera de elección para el diagnóstico, pero presenta complicaciones metodológicas y se asocia a efectos adversos. Los neonatos presentan aumento de la secreción de HC de forma fisiológica, siendo una ventana diagnóstica. OBJETIVO: Evaluar si la muestra de sangre en papel filtro tomada en el período neonatal, en contexto del tamizaje neonatal de hipotiroidismo congénito y fenilcetonuria, permite diferenciar pacientes con DHC, de los que no la presentan. PACIENTES Y MÉTODO: Estudio de casos y controles mediante determinación de concentración de HC en sangre de papel filtro extraída en período neonatal, comparando controles con DHC con casos con deficiencia descartada. Se realizó extracción de la muestra del papel filtro, obteniendo dos discos de 0,125 pulgada por cada uno de los pacientes desde el centro de la mancha de sangre del papel, para un ELISA de HC humana altamente sensible basado en el uso de anticuerpos policlonales dirigidos contra la HC humana recombinante de 22kDa de peso molecular. RESULTADOS: Se obtuvo un total de 7 casos de DHC y 10 controles. La mediana de concentración de HC de papel filtro en los casos es 2,0 ng/ml (Rango intercuartil 3,6 ng/ml) y controles 2,05 ng/mL (RIC 2,0 ng/ml), U de Mann-Withney 30,5 (p = 0,68). Los dos casos con deficiencia de hormonas hipofisarias múltiples (DHHM) presentan concentraciones menores a 1 ng/ml. CONCLUSIÓN: La muestra de papel filtro no permitió diferenciar a los pacientes con DHC de los casos controles, aunque los casos con DHHM presentaron concentraciones mucho menores, en comparación a la deficiencia de hormona de crecimiento aislada (DHCA).

INTRODUCTION: The diagnosis of growth hormone deficiency (GHD) is difficult to determine, and could be associated with severe complications, especially in the neonatal period. The stimulation test of growth hormone (GH) secretion is considered the gold standard for diagnosis, but it has methodological complications and is associated with adverse effects. Neonates present physiological increased secretion of GH, representing a diagnostic window. OBJECTIVE: To evaluate if the dried blood spot on filter paper obtained in the neonatal period, as part of a neonatal screening for con genital hypothyroidism and phenylketonuria, allows differentiating patients with GHD from those who do not have it. PATIENTS AND METHOD: Study of cases and controls by measuring the GH concen tration in dried blood spot on filter paper obtained in the neonatal period, comparing controls with GHD with cases with discarded deficiency. The sample was extracted from the filter paper, obtaining two 0.125 inch discs per each patient from the center of the blood spot on the paper, for a highly sen sitive ELISA assay for human GH based on the use of polyclonal antibodies against 22 kDa recom binant human GH. RESULTS: Seven cases of GHD and ten controls were obtained. The median GH concentration of the dried blood spot in the cases is 2.0 ng/ml (Interquartile range 3.6 ng/ml) and 2.05 ng/ml (Interquartile range 2.0 ng/ml) in the controls, Mann-Whitney U test 30.5 (p = 0.68). The two cases with multiple pituitary-hormone deficiency (MPHD) present concentrations lower than 1 ng/ml. CONCLUSION: The dried blood spot sample did not differentiate GHD patients from control cases, although MPHD cases present much lower concentrations compared to isolated growth hor mone deficiency (IGHD).

The role of insulin like growth factor (IGF)–1 and IGF-binding protein-3 in diagnosis of growth hormone deficiency in short stature children.

Objective. To evaluate the role of IGF-1 and IGFBP-3 in diagnosis of short stature children and adolescents in whom Growth Hormone Deficiency (GHD) was found. Methods. In this cross sectional study the referred short stature children and adolescents to Namazi Hospital in Shiraz- Iran, in 2003-2005 were studied. The inclusion criteria were proved short stature based on the physical examination, weight, height, standard deviation score (SDS) of height < -2 , with considering stage of puberty and predicted height in children without any genetic or chronic disorders. The exclusion criteria were any positive physical or laboratory data suggesting hypothyroidism, rickets or liver disorders. For all patients a provocative growth hormone test was performed with propranolol and L-dopa and serum IGF-1 and IGFBP-3 were measured. GHD defined as peak(cutoff ) serum GH level under 10 ìg/L and low IGF-1 and IGFBP-3 considered as cutoff serum level under -2 standard deviation. Results. Eighty one short stature patients (39 boys and 42 girls) with mean age of 10.6 ± 3.5 years completed the study. Seventeen patients with GHD were found and in 18 patients IGF-1 level were low. Only in 6 patients both GH and IGF-1 were low and 2 of them had low IGFBP-3. There were no correlations between the levels of GH,IGF-1 and IGFBP-3 in children with short stature due to GHD. The sensitivity and specifity of IGF-1 and IGFBP-3 in assessment of GHD were 35% and 81% for IGF-1 and 12% and 94% for IGFBP-3, respectively. Conclusion. No correlations were found between GH level and serum levels of IGF-1 and IGFBP-3 in short patients and the sensitivity of these tests in assessment of GHD was poor.

Evaluation of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in diagnosis of growth hormone deficiency in short-stature children

Growth Hormone Deficiency [GHD] is conventionally diagnosed and confirmed by diminished peak Growth Hormone [GH] levels to provocative testing. Serum Insulin-like growth factor-1 [IGF-1] and insulin-like growth factor binding protein-3 [IGFBP-3] are under the influence of GH and reflect the spontaneous endogenous GH secretion. Owing to the absence of a circadian rhythm, it is possible to take individual measurements of IFG-1 and IGFBP-3 assays with Exercise and L-Dopa stimulation tests in the diagnosis of growth hormone deficiency in short stature children using ITT as gold standard. This validation study was conducted at Department of Chemical Pathology and Endocrinology, AFIP, Rawalpindi, from November 2005 to October 2006. Fifty-two short stature children were included in the study. Basal samples for GH levels and simultaneous IGF-1 and IGFBP-3 measurements were obtained and afterwards all children were subjected to sequential exercise and L-Dopa stimulation tests. Insulin Tolerance Test [ITT] was performed one week later with all the necessary precautionary measures. On the basis of ITT results, children were divided into two groups, i.e., 31 growth hormone deficient and 21 Normal Variant Short Stature [NVSS]. The diagnostic value of exercise stimulation test remained highest with sensitivity 90.3%, specificity 76.0%, Positive Predictive Value [PPV] 84.84%, Negative Predictive Value [NPV] 84.2% and accuracy 84.6%. The conventional L-Dopa stimulation had sensitivity 96.7%, specificity 38.0%, PPV 69.7%, NPV 88.8% and accuracy 73.0%. The serum IGF-1 and IGFBP-3 levels were positively correlated with post ITT peak GH levels [r=0.527, r=0.464 respectively, both p<0.001]. The diagnostic value of IGF-1 had sensitivity 83.87%, specificity 76.2%, PPV 83.87%, NPV 76.2% and accuracy 80.76%. The diagnostic value of IGFBP-3 had sensitivity 54.83%, specificity 90.47%, PPV 89.47%, NPV 57.57% and accuracy 69.23%. With combined use of IGF-1 and IGFBP-3 diagnostic value had sensitivity 69.35%, specificity 83.33% PPV 86%, NPV 64.81% and accuracy 75%. Growth Hormones provocative tests still remain the most useful investigations for the diagnosis of GHD. Measurements of IGF-1 and IGFBP-3 have shown comparable diagnostic performance with growth hormone stimulation tests and are valuable for patients' convenience and ease of performance and can be useful in the initial workup of short stature

Avaliação dos métodos diagnósticos para deficiência de GH (DGH) na infância: IGFs, IGFBPs, testes de liberação, ritmo de GH e exames de imagem: [revisão] / Evaluating diagnosis methods on childhood GH (DGH) deficiency: IGFs, IGFBPs, releasing tests, GH rhythm and image exams: [review]

O emprego das diversas metodologias diagnósticas da deficiência de hormônio de crescimento (DGH) em crianças é controverso. Neste artigo serão analisadas estas alternativas revisando a literatura e apresentando dados prospectivos obtidos pelos autores, sugerindo que a DGH seja diagnosticada empregando-se testes de triagem seguidos de testes de confirmação. Assim, recomenda-se que crianças com baixa estatura sejam avaliadas clínica e laboratorialmente para exclusão de doenças crônicas e genéticas. Naquelas com estatura < 3º percentil ou velocidade de crescimento (VC) < percentil 25, dosar IGF-1 como triagem. Se IGF-1 < -1 desvio-padrão (DP), a DGH deve ser confirmada pela ausência de resposta do hormônio de crescimento (GH) a dois testes de estímulo (pico < 5 mcg/L). Em paciente com fatores de risco, IGF-1 < -1 DP e um teste não-responsivo também é diagnóstico de DGH. As crianças com IGF-1 > -1 DP, devem ter a VC acompanhada e, se alterada, pode-se indicar reavaliação do eixo GH/IGF-1 excluindo ou confirmando a DGH.

The diagnostic approach to growth hormone deficiency (GHD) in children with short stature (SS) is controversial. Here we review the available methodology and present prospective data obtained in a cohort of patients with SS suggesting the use of screening test followed by the confirmation test. Thus, the children with SS should be submitted to clinical and laboratorial evaluation to exclude of chronic and genetic diseases. In addition patients with height < 3 percentil or growth velocity < percentil 25, IGF-1 levels should be measured. If the IGF1 levels < -1 standard deviation (SD) compared to the age, GHD should be confirmed by two GH-stimulations tests (peak < 5 mcg/L). In risk factor patients, IGF-1 < -1 SD and one non-responsible GH-test, the GHD was confirmed. Children with IGF-1 > -1 SD, the growth velocity should have observed and GH/IGF-1 axis re-evaluated if the growth pattern is not satisfactory.

Basal encephalocele associated with morning glory syndrome: case report

The basal encephaloceles refer to rare entities and they correspond to herniation of brain tissue through defects of skull along the cribiform plate or the sphenoid bone. A rare morning glory syndrome, with characteristic retinal defect has been reported in association with basal encephaloceles. Hypophysis hormonal deficiencies may occur. We accounted for a pituitary dwarfism with delayed diagnosed transsphenoidal encephalocele associated with morning glory syndrome, showing the alterations found in retinography, computed tomography and magnetic resonance imaging.

As encefaloceles basais são entidades raras e correspondem a herniações do tecido cerebral através de um defeito do crânio, ao longo da lâmina crivosa etmoidal ou do osso esfenoidal. A rara síndrome morning glory, com alterações de fundo de olho características pode apresentar-se associada à encefalocele basal. Deficiências hormonais hipofisárias podem ocorrer. Relatamos caso de nanismo hipofisário com encefalocele transesfenoidal de diagnóstico tardio associada à síndrome de morning glory, mostrando as alterações na retinografia, tomografia computadorizada e ressonância magnética.

Diagnosis and growth hormone (GH) therapy in children with GH deficiency: experience in King Chulalongkorn Memorial Hospital, Thailand.

BACKGROUND: Diagnosis of growth hormone deficiency (GHD) needs both clinical and biological aspects such as auxological data and GHprovocative tests, and active metabolites of GH including IGF-I and IGFBP-3. In GHD children, rhGH has been used worldwide with minimal serious side effects. The aims of the present study were to describe the experience in King Chulalongkorn Memorial Hospital regarding diagnosis and treatment with rhGH in GHD children. MATERIAL AND METHOD: Clinical data of 173 short children was retrospectively reviewed. Two GH provocative tests used in the present study were insulin tolerance test (ITT) and clonidine test. To make the diagnosis of GHD, the children had to fail both GH provocative tests (peak GH < 10 ng/ml). Baseline clinical data, IGF-I, and IGFBP-3 were compared between the group with true positive test and the group with false positive test. Thirty-five children with GHD, who had been treated with rhGH, were evaluated in terms of growth response, changes of IGF-I SDS and the relationship between these parameters. RESULTS: From the present study, ITT could diagnose GHD with true positive 57% and false positive 43% and clonidine could diagnose with true positive 67% and false positive 33%. Clinical data including chronological age, bone age, HtSDS, WtSDS, IGF-I SDS, and IGFBP-3 SDS were not different between the true positive and false positive group. rhGH with a mean dose of 29.3 +/- 4.6 microg/kg/day increased height velocity (HV) from 3.9 +/- 2.5 to 9.3 +/- 2.5, 8.1 +/- 1.5, 7.2 +/- 2.2, 6.8 +/- 2.2, 7.6 +/- 2.4, and 6.5 +/- 1.8 cm/yr after 6 months, 1, 2, 3, 4, and 5 years after treatment, respectively. This also improved HtSDS during treatment and brought the HtSDS into the target range after 3 years of treatment. At the end of the first year of treatment, the difference of IGF-I SDS (DeltaIGF-I SDS) > or = 1 could predict a good response (DeltaHtSDS > or = 0.5) with sensitivity of 88.9% and specificity of 60% respectively. At the end of the second year, DeltaIGF-I SDS > or = 1 could predict a good response with sensitivity and specificity of 100% and 29%, respectively. CONCLUSION: From the present study, the authors demonstrated the investigation and treatment practices of short children with GHD. The growth response is satisfactory even with a lower dose than suggested. In addition, measurement of IGF-I and IGFBP-3 cannot be used in diagnosing GHD but can predict the height outcome at least by the first 2 years of the treatment. However long-term outcome need to be clarified.

Estudo do gene LHX4 em pacientes com hipopituitarismo associado a neuro-hipófise ectópica / Molecular analysis of the LHX4 gene in hypopituitary patients with ectopic posterior pituitary lobe

O fenótipo dos pacientes com mutação do LHX4 em humanos é caracterizado por hipopituitarismo associado a neuro-hipófise ectópica. O objetivo do estudo é verificar a presença de mutações no LHX4 em 63 pacientes com o citado fenótipo. Os pacientes foram submetidos à avaliação hormonal e por imagem através de ressonância magnética. A análise molecular incluiu amplificação do gene por PCR, sequenciamento automático direto e uso de enzima de restrição. Encontramos deficiência hipofisária múltipla em 81 por cento dos pacientes. A neuro-hipófise foi localizada na eminência média em 35 por cento dos pacientes com haste visualizada e em 33 por cento dos pacientes sem haste visualizada. Identificamos 5 novas variações alélicas e três delas caracterizamos como polimorfismos. Concluímos que mutações no LHX4 são causas raras de hipopituitarismo / LHX4 gene mutation phenotype is characterized by hypopituitarism associated to ectopic posterior pituitary lobe (EPL). To investigate clinical characteristics and LHX4 mutations in 63 patients with this phenotype, evaluation of pituitary function, imaging and molecular analysis of LHX4 using PCR, automatic sequencing and restriction enzyme were performed. Combined pituitary hormone deficiency was found in 81 per cent of patients. The EPL was located at median eminence in 35 per cent of patients with visualized pituitary stalk and in 33 per cent of patients without visualized pituitary stalk. We found five new allelic variations, three of them characterized as new polymorphisms without clear relationship to the phenotype. LHX4 gene mutations remain rare causes of hypopituitarism associated to EPL...

Enanismo pituitario canino: reporte de un caso / Canine pituitary dwarfism: a report of one case

El enanismo pituitario es una endocrinopatía ocasionada por la deficiencia de hormona de crecimiento. La imposibilidad de medir esta hormona en los caninos ha ocasionado que, muchas veces, no se considere al enanismo pituitario entre los diagnósticos diferenciales de retraso del crecimiento y dermatopatía en el cachorro. En el presente trabajo se describen dos casos clínicos de esta enfermedad en caninos, los cuales una vez referidos a la Facultad de Ciencias Veterinarias de La Plata, Argentina, se confirmó el diagnóstico de enanismo pituitario. La posibilidad de dosificar la hormona de crecimiento canina mediante radioinmunoensayo origina perspectivas alentadoras en el conocimiento, de la prevalencia de esta enfermedad en los caninos

Enanismo asociado a panhipopituitarismo con neurohipófisis ectópica, sin diabetes insípida / Dwarfism associated at panhypopituitarism with ectopic neurohypophysis without diabetes insipidus

We are introducing a patient of 22 years old who suffers from Dwarfness and primary Amenorrhea. She showed dosages of basal somatotrophin and post estimulation of 0.5 ng/ml or less, somatomedin (IGF1): 2.40 ui/ml, rudiment uterus and annexes with normal karyotype 46xx. RMN of Sella Turcica and adjacencies showed; a posterior pituitary lobe ectopy, with the conservation of his hypothalamic conexion and hormonal deficit of L.A. (suprarenal, gonadal and somatotrophic axes). The use of RMN allowed us to evaluate and thus reached a precise diagnosis in reference to the hypothalamic lesion.

Anormalidades hipotálamopituitarias en enanismo pituitario "idiopático" / Hypothalamus-pituitary abnormalities in \"idiopathic\" dwarfism pituitary

Entre Enero de 1995 y Mayo de 1997 fueron evaluados 8 niños con diagnóstico de deficiencia de hormona de crecimiento (GH) en el Servicio de Endocrinología del Hospital Nacional "Guillermo Almenara Irigoyen", cuyas edades estaban comprendidas entre 1.3 y 12.5 años. El estudio realizado fue descriptivo, prospectivo y no probabilístico. Todos los niños tuvieron una talla inferior a 3 DS de la media, velocidad de crecimiento disminuida y edad ósea menor a 3 DS en relación a la edad cronológica. El 71.4 por ciento de los niños tuvo el antecedente de asfixia perinatal o parto traumático. El 100 por ciento evidenció deficiencia de GH, 71.4 por ciento deficiencia de Cortisol, el 50 por ciento hipotiroidismo secundario y el 12.5 por ciento diabetes insípida central parcial. 5 pacientes (62.5 por ciento) presentaron deficiencia de GH y Cortisol, 4(50 por ciento) de GH y TSH, y 3 (37.5 por ciento) de GH, Cortisol, y TSH. La tomografía axial computarizada (TAC) de silla turca no fue contributorio en ninguno de los pacientes; y la Resonancia Mágnetica Nuclear (RMN) mostró en los pacientes con deficiencia de dos o más hormonas, alteración de la adenohipófisis en el 100 por ciento, ausencia del tallo pituitario en el 71.4 por ciento, y neurohipófisis ectópica en el 57.1 por ciento de ellos. En el único paciente con deficiencia aislada de GH, la RMN fue normal. Se concluye que en los pacientes con enanismo por deficiencia de GH pueden tener deficiencia de otras hormonas hipofisiarias por lo que se debe realizar estudios dinámicos de la reserva de la adenohipófisis y de la neurohipófisis. En los pacientes con deficiencia hormonal se ha encontrado alteraciones anatómicas de la región hipotálamo-pituitaria en la RMN.

Empty sella in short children with and without hypothalamic-pituitary abnormalities.

A study was conducted on growth hormone (GH) response to oral clonidine (0.15 mg/m2), GH and cortisol responses to i.m. glucagon (0.1 mg/kg), and glucose response to an oral load of glucose (1.75 g/kg). Measurements were made on the circulating concentrations of free thyroxine (FT4), thyroid stimulating hormone (TSH) and different growth parameters and CT sellar images in 25 GH deficient children (Peak GH response to clonidine and glucagon < 7 ug/ml), 15 growth retarded children (Ht < 5th percentile for age and gender) with sickle cell disease (SCD) and GH deficiency, 30 randomly selected children with normal variant short stature (NVSS) (HtSDS 2SD below the mean for age and gender with normal GH response to stimulation (> 10 ug/ml) and 20 age-matched normal children were evaluated. Out of the 25 children with GH deficiency, five had multiple pituitary hormonal deficiency (GH < TSH and/or ACTH. deficiencies), and 20 had isolated GH deficiency. Empty sella, either complete or partial, was detected in 9 out the 20 children with isolated GH deficiency (45%), 4 out of the 5 children with multiple pituitary deficiency (80%), all the children with SCD and GH deficiency (100%), 3 out of the 30 children with NVSS (10%) and in none of the normal children. The insulin-like growth factor-I (IGF-I) concentrations were significantly lower in the two groups of children with GH deficiency compared to those with NVSS. The height standard deviation scores (HTSDS) were significantly lower and the annual growth velocity was slower in children with idiopathic GH deficiency and empty sella compared to those with NVSS and those with empty sella associated with SCD. The bone age delay (yr) did not differ among the 3 groups of children with short stature. All children with isolated GH deficiency associated with empty sella had normal body mass indices (BMI), while all the children with SCD and empty sella had BMI below the 5th percentile for the corresponding age and gender. None of the children had glucose intolerance. In conclusion, children with growth retardation and abnormal hypothalamic pituitary functions have high incidence of empty sella. However, empty sella is detected in considerable number (10%) of short children with normal hypothalamic pituitary function.

Deficiência de hormônio do crescimento / Growth hormone deficiency

Analisam-se um grupo de pacientes com deficiência de hormônio do crescimento (DHC), incluidos no Programa do Hormônio do Crescimento do INAMPS-RS, do Hospital Materno Infantil Presidente Vargas (HMIPV). Estes pacientes submeteram-se ao tratamento com o hormônio do crescimento (HC) por um período médio de três e meio a quatro anos. Foram estudados a prevalência de sexo, etiologia e classificaçäo da DHC. Deste grupo inicial, doze crianças foram avaliadas separadamente, a fim de um estudo mais acurado das condiçöes de nascimento e do crescimento antes e após o tratamento com HC. Junta-se a estes dados uma revisäo da literatura